公开(公告)号：US07074789B2

公开(公告)日：2006-07-11

申请号：US10699518

申请日：2003-10-31

申请人： David M. Armistead ,  Jean E. Bemis ,  John L. Buchanan ,  Lucian V. DiPietro ,  Daniel Elbaum ,  Stephanie D. Geuns-Meyer ,  Gregory J. Habgood ,  Joseph L. Kim ,  Teresa L. Marshall ,  Perry M. Novak ,  Joseph J. Nunes ,  Vinod F. Patel ,  Leticia M. Toledo-Sherman ,  Xiaotian Zhu

发明人： David M. Armistead ,  Jean E. Bemis ,  John L. Buchanan ,  Lucian V. DiPietro ,  Daniel Elbaum ,  Stephanie D. Geuns-Meyer ,  Gregory J. Habgood ,  Joseph L. Kim ,  Teresa L. Marshall ,  Perry M. Novak ,  Joseph J. Nunes ,  Vinod F. Patel ,  Leticia M. Toledo-Sherman ,  Xiaotian Zhu

IPC分类号： C07D403/12 ,  C07D403/14 ,  A61K31/4155 ,  A61P35/04

CPC分类号： C07D401/04 ,  C07D251/18 ,  C07D251/22 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The invention relates to inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms.

摘要翻译： 本发明涉及结合ATP或GTP和/或催化磷酸转移的酶抑制剂，包含抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包含它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备磷酸转移酶抑制剂化合物的方法，抑制磷酸转移酶活性的方法，以及治疗疾病或疾病症状的方法。

公开(公告)号：US07282504B2

公开(公告)日：2007-10-16

申请号：US11125614

申请日：2005-05-09

申请人： David M. Armistead ,  Jean E Bemis ,  Lucian V DiPietro ,  Stephanie D. Geuns-Meyer ,  Gregory J. Habgood ,  Joseph L. Kim ,  Joseph J. Nunes ,  Vinod F. Patel ,  Leticia M. Toledo-Sherman

发明人： David M. Armistead ,  Jean E Bemis ,  Lucian V DiPietro ,  Stephanie D. Geuns-Meyer ,  Gregory J. Habgood ,  Joseph L. Kim ,  Joseph J. Nunes ,  Vinod F. Patel ,  Leticia M. Toledo-Sherman

IPC分类号： C07D403/04 ,  A61K31/404

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14

摘要： The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

摘要翻译： 本发明涉及激酶抑制剂，包含抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包含它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备激酶抑制剂化合物的方法，抑制激酶活性的方法，以及治疗疾病或疾病症状的方法。

公开(公告)号：US06495558B1

公开(公告)日：2002-12-17

申请号：US09528976

申请日：2000-03-21

申请人： David M. Armistead ,  Jean E. Bemis ,  Daniel Elbaum ,  Gregory J. Habgood ,  Perry M. Novak ,  Joseph J. Nunes ,  Leticia M. Toledo-Sherman

发明人： David M. Armistead ,  Jean E. Bemis ,  Daniel Elbaum ,  Gregory J. Habgood ,  Perry M. Novak ,  Joseph J. Nunes ,  Leticia M. Toledo-Sherman

IPC分类号： C09D23936

CPC分类号： C07D239/47 ,  C07D239/56 ,  C07D239/70

摘要： The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

摘要翻译： 本发明涉及激酶抑制剂，包含抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包含它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备激酶抑制剂化合物的方法，抑制激酶活性的方法，以及治疗疾病或疾病症状的方法。

公开(公告)号：US20130029988A1

公开(公告)日：2013-01-31

申请号：US13575019

申请日：2011-01-20

申请人： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Dirk Winkler ,  Frederick Brookfield ,  Paula C. De Aguiar Pena

发明人： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Dirk Winkler ,  Frederick Brookfield ,  Paula C. De Aguiar Pena

IPC分类号： C07D403/04 ,  A61K31/505 ,  A61K31/506 ,  C07D413/04 ,  C07D413/14 ,  A61P25/08 ,  C07D401/04 ,  A61K31/513 ,  C07D417/04 ,  A61P25/28 ,  A61P25/16 ,  A61P25/00 ,  C07D239/28 ,  A61K31/5377

CPC分类号： C07D403/04 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4245 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US20160251318A1

公开(公告)日：2016-09-01

申请号：US14241374

申请日：2012-08-28

申请人： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

发明人： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Munoz

IPC分类号： C07D239/28 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D401/12 ,  C07D405/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10 ,  C07D413/04 ,  C07D471/04 ,  C07D409/04 ,  C07D417/04 ,  C07D403/10 ,  C07D405/10 ,  C07D401/04

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学物质和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US09428464B2

公开(公告)日：2016-08-30

申请号：US14241699

申请日：2012-08-28

申请人： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Muñoz-Sanjuan

发明人： Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson ,  Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Ignacio Muñoz-Sanjuan

IPC分类号： C07D239/52 ,  A61K31/506 ,  C07D239/28 ,  C07D403/12 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D491/048 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D239/28 ,  A61K31/506 ,  C07D239/42 ,  C07D239/52 ,  C07D401/04 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/465

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US20140329816A1

公开(公告)日：2014-11-06

申请号：US14235253

申请日：2012-07-26

申请人： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson

发明人： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson

IPC分类号： C07D417/04 ,  C07D401/04 ,  C07D413/04 ,  C07D413/14 ,  C07D239/28 ,  C07D403/04

CPC分类号： A61K31/506 ,  A61K31/505 ,  A61K31/513 ,  A61K31/5377 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US09981918B2

公开(公告)日：2018-05-29

申请号：US14241374

申请日：2012-08-28

申请人： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  Peter Johnson ,  Ignacio Muñoz-Sanjuán ,  Stephen Martin Courtney ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena

发明人： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  Peter Johnson ,  Ignacio Muñoz-Sanjuán ,  Stephen Martin Courtney ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena

IPC分类号： C07D237/28 ,  A61K31/70 ,  C07D239/28 ,  C07D405/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D239/42 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US08691824B2

公开(公告)日：2014-04-08

申请号：US13056919

申请日：2009-08-03

申请人： John Wityak ,  Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Stephen Martin Courtney ,  Christopher John Yarnold ,  Paula C. De Aguiar Pena ,  Andreas Scheel ,  Dirk Winkler

发明人： John Wityak ,  Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Stephen Martin Courtney ,  Christopher John Yarnold ,  Paula C. De Aguiar Pena ,  Andreas Scheel ,  Dirk Winkler

IPC分类号： A61K31/497

CPC分类号： A61K31/42 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/465

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对KMO活性的抑制作用的某些疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：US20130331370A1

公开(公告)日：2013-12-12

申请号：US13963822

申请日：2013-08-09

申请人： John Wityak ,  Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Stephen Martin Courtney ,  Christopher John Yarnold ,  Paula C. De Aguiar Pena ,  Andreas Scheel ,  Dirk Winkler

发明人： John Wityak ,  Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Stephen Martin Courtney ,  Christopher John Yarnold ,  Paula C. De Aguiar Pena ,  Andreas Scheel ,  Dirk Winkler

IPC分类号： C07D239/52 ,  C07D403/12 ,  C07D401/12 ,  C07D239/38 ,  C07D239/69

CPC分类号： C07D239/52 ,  A61K31/505 ,  A61K31/506 ,  C07D213/79 ,  C07D213/81 ,  C07D239/28 ,  C07D239/38 ,  C07D239/42 ,  C07D239/69 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/465

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.